MULTIPLE MYELOMA PATIENTS ON CHRONIC DIALYSIS IN URUGUAY: ANALYSIS OF THE LAST 40 YEARS

Introduction:

Multiple myeloma can cause end stage renal disease requiring renal replacement therapy. The aim of this study is to analyze the clinical presentation, evolution and prognosis of patients admitted to chronic dialysis in Uruguay between 1981 and 2020 with multiple myeloma associated nephropathies. 

Methods:

This is a descriptive and retrospective study, based on the Uruguayan Dialysis Registry, the Glomerulopathies Prevention and Treatment Program and the data from state office that finances treatment.

Results:

 We analyzed 287 patients with a mean age of 65.1±12.1 years, 92.3% of whom started hemodialysis. 24.4% of patients had a renal biopsy, with amyloidosis being the most frequent diagnosis. We observed an increase in the incidence rate of patients with multiple myeloma, which went from 0.55 pmp in the first five-year period analyzed (1981-1984) to 3.77 pmp in the last period (2015-2020) (Figure 1). The 100-month survival rate of patients who received the drug was higher (41; 95% CI 31-52 months) than that of those who did not (26; 95% CI 21-32 months) (p=0.014) (Figure 2). 

Conclusions:

Patients treated with bortezomib had a higher survival rate, which was surely contributed to by the improvement in nephrological and hematological care in recent years.

I have no potential conflict of interest to disclose.

I did not use generative AI and AI-assisted technologies in the writing process.